×
About 618 results

ALLMedicine™ Paronychia Center

Research & Reviews  177 results

Paronychia
http://emedicine.medscape.com/article/1106062-overview

May 10th, 2022 - Practice Essentials Paronychia is a soft tissue infection around a fingernail or toenail that begins as cellulitis but that may progress to a definite abscess. [1] The 2 types of paronychia are as follows [2] : Acute paronychia - Painful and purul...

Paronychia Treatment & Management
http://emedicine.medscape.com/article/1106062-treatment

May 10th, 2022 - Approach Considerations The treatment of choice depends on the extent of the infection. If diagnosed early, acute paronychia without obvious abscess can be treated nonsurgically. If soft tissue swelling is present without fluctuance, the infection...

Usefulness of Noninvasive Management With the Gutter Method for Epidermal Growth Factor...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008561
JAMA Dermatology; Agematsu A, Kamata M et. al.

Apr 14th, 2022 - Usefulness of Noninvasive Management With the Gutter Method for Epidermal Growth Factor Receptor Inhibitor-Induced Paronychia, Pyogenic Granuloma-Like Lesion, and Ingrown Nail.|2022|Agematsu A,Kamata M,Namiki K,Yabuuchi Y,Nagata M,|

Metabolic complete tumor response in a patient with epidermal growth factor receptor mu...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943310
The Journal of International Medical Research; Puliafito I, Esposito F et. al.

Mar 17th, 2022 - Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are the first-line treatment for EGFR-mutant non-small cell lung cancer. Toxicities related to EGFR-TKIs include skin rash, paronychia, and diarrhea, which in some...

Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carc...
https://doi.org/10.1158/1078-0432.CCR-21-3025
Clinical Cancer Research : an Official Journal of the Ame... Kao HF, Liao BC et. al.

Jan 21st, 2022 - EGFR pathway inhibition may promote anti-programmed cell death protein 1 (PD-1) responses in preclinical models, but how EGFR inhibition affects tumor antigen presentation during anti-PD-1 monotherapy in humans remain unknown. We hypothesized that...

see more →

Guidelines  1 results

Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibito...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532717
Drugs Califano R, Tariq N et. al.

Jul 19th, 2015 - Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, and afatinib are standard-of-care for first-line treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). These drugs have a prove...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  2 results

Subclinical Nail Involvement in Relevant Skin Diseases
https://clinicaltrials.gov/ct2/show/NCT04092413

Sep 17th, 2019 - Nails are characteristically affected in skin diseases such as psoriasis (speckling, psoriatic oil spot, crumbling nails, pachyonychia) ,lichen( anonychia, dystrophy) ,alopecia areata (speckling, trachyonychia, longitudinal grooves, leukonychia), ...

Therapeutic Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors
https://clinicaltrials.gov/ct2/show/NCT03047863

Feb 10th, 2017 - Epidermal growth factor receptor(EGFR) is involved in cell proliferation and is overexpressed or abnormally activated in malignant tumors originating from the colon, breast, ovary, pancreas, and lung. EGFR tyrosine kinase inhibitor(TKI), gefitinib...

see more →

News  64 results

NSCLC: Mobocertinib for Patients With EGFR Exon 20 Insertion Mutations
https://www.onclive.com/view/nsclc-mobocertinib-for-patients-with-egfr-exon-20-insertion-mutations

Oct 27th, 2021 - Transcript: Erminia Massarelli, MD, MS, PhD: The mechanism of action of mobocertinib [Exkivity] is an irreversible EGFR tyrosine kinase inhibitor. However, it differs from osimertinib [Tagrisso], which is currently approved for exon 19 and21 muta...

Once-Daily Poziotinib Shows Efficacy in NSCLC HER2 Exon 20 
https://www.medscape.com/viewarticle/959923

Sep 29th, 2021 - Once-daily dosing of poziotinib shows clinically meaningful efficacy for patients with treatment-naive non–small cell lung cancer (NSCLC) HER2 exon 20 mutations, according to results of the ZENITH20 trial presented at the 2021 European Society for...

Lung Cancer Pioneer Paves Path for Future Innovation
https://www.onclive.com/view/lung-cancer-pioneer-paves-path-for-future-innovation-

Sep 24th, 2021 - When Haiying Cheng, MD, PhD, was testing a plastic tent for the first-inhuman trial of inhaled azacitidine to treat patients with advanced non–small cell lung cancer (NSCLC), she had an unusual subject zero: Roman Perez-Soler, MD, the highly accom...

Review eyes nail unit toxicities secondary to targeted cancer therapy
https://www.mdedge.com/dermatology/article/244613/hair-nails/review-eyes-nail-unit-toxicities-secondary-targeted-cancer
Doug Brunk

Aug 24th, 2021 - Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies, while damage to other nail unit anatomic areas can be wide-ranging. Those are key findings from an evi.

Review Eyes Nail Unit Toxicities Secondary to Targeted Cancer Therapy
https://www.medscape.com/viewarticle/957155

Aug 24th, 2021 - Paronychia and periungual pyogenic granulomas are the most common nail unit toxicities related to targeted cancer therapies and immunotherapies, while damage to other nail unit anatomic areas can be wide-ranging. Those are key findings from an evi...

see more →

Patient Education  1 results see all →